Steven M Rowe MD
Critical Care Medicine, Pleural Disease
Assistant Professor, Medicine, University of Alabama School of Medicine
Join to View Full Profile
1717 6th Ave SBirmingham, AL 35233
Phone+1 800-822-8816
Fax+1 205-934-1721
Dr. Rowe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Alabama Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2002 - 2006- University of Alabama Medical CenterResidency, Internal Medicine/Pediatrics, 1998 - 2002
Vanderbilt University School of MedicineClass of 1998
Certifications & Licensure
AL State Medical License 1999 - 2025
Clinical Trials
- Nasal Potential Studies Utilizing Cystic Fibrosis Transmembrane Regulator (CFTR) Modulators Start of enrollment: 2010 Mar 01
- G551D Observational Study- Expanded to Additional Genotypes and Extended for Long Therm Follow up (GOAL-e2) Start of enrollment: 2014 Jan 01
- TOPIC Trial for COPD Start of enrollment: 2015 May 01
- Join now to see all
Publications & Presentations
PubMed
- Cholesterol and triglyceride concentrations following 12-18 months of clinically prescribed elexacaftor-tezacaftor-ivacaftor-PROMISE sub-study.Rosara Bass, Michael Stalvey, George Solomon, Steven Rowe, David Nichols
Journal of Clinical & Translational Endocrinology. 2025-06-01 - Lumacaftor inhibits channel activity of rescued F508del cystic fibrosis transmembrane conductance regulator.Adam D Ambrosetti, Zachary J Hagedorn, Taylor R Bono, Hui Wen, Rodney Nguyen
American Journal of Physiology. Lung Cellular and Molecular Physiology. 2025-05-07 - Toward in vivo bronchoscopic functional CFTR assessment using a short circuit current measurement probe.David O Otuya, Zhongyu Liu, Reny Joseph, Mohammed A Hanafy, Kadambari Vijaykumar
American Journal of Physiology. Lung Cellular and Molecular Physiology. 2025-02-01
Journal Articles
- Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized TrialSteven Rowe, MD, Dove Press
- Ivacaftor Improves Rhinologic, Psychologic, and Sleep‐Related Quality of Life in G551D Cystic Fibrosis PatientsBradford A Woodworth, Justin McCormick, Steven M Rowe, Brooks Lampkin, International Forum of Allergy & Rhinology
- Non-Obstructive Vas Deferens and Epididymis Loss in Cystic Fibrosis RatsJ S Hong, E J Sorscher, S M Rowe, ScienceDirect
- Join now to see all
Press Mentions
- Interdisciplinary Work Highlighted at COVID-19 Research SymposiumOctober 29th, 2020
Minimally Invasive Imaging Device Shows Changes in Nasal Airways, May Allow Earlier CF DiagnosisAugust 13th, 2019
New Intra-Nasal Imaging to Study Airways in Patients with Cystic FibrosisAugust 7th, 2019- Join now to see all
Grant Support
- Therapeutic targeting of MUC5B in a novel ferret model of idiopathic pulmonary fibrosisUNIVERSITY OF ALABAMA AT BIRMINGHAM2020–2025
- Clinical And Translational CoreNational Institute Of Diabetes And Digestive And Kidney Diseases2012
- Molecular Pathogenesis And Phenotype Of Acquired CFTR Dysfunction In COPDNational Heart, Lung, And Blood Institute2011–2012
- Mechanistic Basis Underlying Protein Repair Of CFTR Nonsense MutationsNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2010
- Clinical And Mechanistic Features Of Premature Termination Codon SuppressionNational Institute Of Diabetes And Digestive And Kidney Diseases2007–2010
- Premature Termination Codon SuppressionNational Institute Of Diabetes And Digestive And Kidney Diseases2006
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
